Clinical trials in Hattiesburg, MS

13 recruiting studies have a site in or near Hattiesburg, MS, Mississippi.

Top conditions here

All conditions

Showing 13 of 13 studies

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Columbus, MS · Grenada, MS · Gulfport, MS · +1147 more sites

RecruitingPhase 3NCT06170788

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Sponsor: Merck Sharp & Dohme LLC

Hattiesburg, MS · +14 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Hattiesburg, MS · +38 more sites

RecruitingPhase 3NCT06976203

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Sponsor: Bristol-Myers Squibb

Hattiesburg, MS · +30 more sites

RecruitingPhase 3NCT07011745

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Sponsor: Bristol-Myers Squibb

Hattiesburg, MS · +41 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Hattiesburg, MS · +225 more sites

RecruitingPhase 2NCT06847321

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Sponsor: Lighthouse Pharmaceuticals, Inc.

Hattiesburg, MS · +38 more sites

RecruitingPhase 3NCT06997497

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Sponsor: Merck Sharp & Dohme LLC

Hattiesburg, MS · +47 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Hattiesburg, MS · +62 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Hattiesburg, MS · +55 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Hattiesburg, MS · +96 more sites

RecruitingPhase not listedNCT00271180

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

Sponsor: Medtronic

Hattiesburg, MS · +112 more sites

RecruitingNot applicableNCT07682597

Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component

Sponsor: Timothy Mullett

Greenville, MS · Greenwood, MS · Gulfport, MS · +10 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.